COPD Foundation, Geisinger, GSK, and Jvion Team Together to Help COPD Patients
Jvion announced a collaboration with the COPD Foundation, Geisinger, GSK to improve the lives of chronic obstructive pulmonary disease (COPD) patients. The four organizations are teaming together to help individuals with COPD stay healthier, avoid hospitalizations, and prevent readmissions following an inpatient stay.
ATLANTA, GA – October 24, 2017– Jvion announced a unique collaboration with the COPD Foundation, Geisinger, and GSK aimed at improving the lives of chronic obstructive pulmonary disease (COPD) patients. Through an innovative approach that leverages cognitive machine technology and COPD patient data, the four organizations are teaming together in an effort to help individuals with COPD stay healthier, avoid hospitalizations, and prevent hospital readmissions following an inpatient stay. COPD encompasses a group of progressive lung diseases that gradually increase breathlessness and wheezing. The disease -- which includes emphysema, chronic bronchitis, refractory (non-reversible) asthma, and some forms of bronchiectasis -- impacts more than 30 million people in the U.S. and is the nation’s third leading cause of death.
The goal of this ‘collaboratory ’ project is to identify COPD patients at risk of hospitalization and most likely to benefit from new medications. The information is generated by Jvion’s Cognitive Clinical Success Machine, which identifies such patients currently under the care of Geisinger. The Cognitive Clinical Success Machine is an advanced artificial intelligence solution built using Eigenspace -- an approach that is a proven asset in solving complex challenges such as quantum mechanics, search and consumer behavior, facial recognition, and now patient deterioration. This Eigen-based solution enables a comprehensive patient view that is amplified beyond the risk of an event to the clinical actions that will improve outcomes and drive patient engagement.
“By combining COPD disease expertise with the exceptional patient care delivered by Geisinger and Jvion’s leading Cognitive Clinical Success Machine, we are positioned to help patients across the nation,” said Craig Kephart, Chief Executive Officer of the COPD Foundation. “This work is intended to demonstrate the power of leading edge, cognitive technology and patient care management to halt instances of rising risk and improve COPD patient lives.”
Funded by GSK, this collaboration brings together the COPD Foundation’s reach and leadership, Geisinger’s patient care expertise, GSK’s innovative respiratory research methods, and Jvion’s market-leading cognitive machine capabilities to identify COPD patients at-risk of an adverse event. The project is divided into two phases. Phase one will target COPD patients who have had an inpatient stay and are at risk of a readmission within 30 days of their initial discharge; phase two will focus on identifying COPD patients at-risk of an avoidable hospitalization.
Ruth Tal-Singer, VP, Medicine Development Leader at GSK said: “GSK is committed to improving the management of patients with COPD using different approaches. We believe that the use of cognitive machine technology will improve our ability to assess the potential of novel therapies for individuals at risk of COPD hospital admission by selecting the right patients for clinical trials and thereby ultimately improving patient outcomes.”
“This work has the potential to revolutionize how we support COPD patients both inside and outside of the hospital,” said Geisinger’s Paul Simonelli, M.D., Director, Thoracic Medicine. “We hope to demonstrate how innovation can improve quality while lowering costs for vulnerable patient populations.”
About the COPD Foundation
The COPD Foundation was established to undertake initiatives that improve the lives of those affected by chronic obstructive pulmonary disease through expanded services for patients and caregivers. The Foundation’s activities focus on achieving these results through research, education, and advocacy programs that will lead to prevention of the disease, and ultimately a cure. For more information about the COPD Foundation please visit https://www.copdfoundation.org.
Geisinger is an integrated health services organization widely recognized for its innovative use of the electronic health record and the development of innovative care delivery models such as ProvenHealth Navigator®, ProvenCare® and ProvenExperience®. As one of the nation’s largest health service organizations, Geisinger serves more than 3 million residents throughout 45 counties in central, south-central and northeast Pennsylvania, and also in southern New Jersey at AtlantiCare, a Malcolm Baldrige National Quality Award recipient. In 2017, the Geisinger Commonwealth School of Medicine and Geisinger Jersey Shore Hospital became the newest members of the Geisinger Family. The physician-led system is comprised of approximately 30,000 employees, including nearly 1,600 employed physicians, 13 hospital campuses, two research centers, and a 583,000-member health plan, all of which leverage an estimated $12.7 billion positive impact on the Pennsylvania and New Jersey economies. Geisinger has repeatedly garnered national accolades for integration, quality and service. In addition to fulfilling its patient care mission, Geisinger has a long-standing commitment to medical education, research and community service. For more information, visit http://www.geisinger.org, or connect with us on Facebook, Instagram, LinkedIn and Twitter.
One of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit http://www.gsk.com.
About Jvion, Inc.
Jvion, Inc. (Jvion) delivers a Cognitive Clinical Success Machine that serves as a high-performance appliance for providers and the healthcare community. It activates macro and micro-level recommendations that help healthcare providers who need ultra-definition patient-level prioritizations, clinical action insights, and suggestions produced with unmatched speed, clinical applicability, and verity. The machine delivers the action-level recommendations that will best reduce the likelihood of an adverse event. This capability is enabled by a cognitive engine driven by horsepower that is based on more than a quadrillion clinical and non-clinical considerations and thousands of data elements. The machine’s thousands of self-learning Eigen spheres are applied to this data for each patient in real time to render an Eigen Propensity Biography that delivers a view into a patient’s total health 30,60,90, up to 365 days in the future. This machine is helping hundreds of hospitals across the nation reduce target illnesses and diseases.
One of the reasons Jvion’s solution is independently ranked number one in clinical predictive science is because the machine is more than accurate, it is effective. Our approach mitigates the “accuracy fallacy” perpetuated within the industry by delivering a true picture of individual patient risk along with adjacent risks and actions that will lead to better health outcomes. Because Jvion’s machine works as a cognitive appliance, it plugs in directly to the existing Electronic Medical Record/clinical systems to deliver recommendations seamlessly into the organic workflow. Clinician and caregiver adoption of Jvion’s recommendations is accelerated because of the “on-demand” nature of the information. The machine outperforms and outsmarts even the highest performing predictive solutions/approaches available. And this performance hasn’t gone unnoticed; Jvion’s solution has won numerous external awards including designation as the #1 Predictive Provider in Healthcare by Black Book Market Research. http://www.jvion.com.